Search results
Results from the WOW.Com Content Network
Another study by Jianren Mao et al. examined how “intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviours in a rat model of peripheral mononeuropathy”. [11] Mao understands that “the experimental neuropathic pain syndrome seen in CCI rats is similar in many respects to the neuropathic pain syndrome seen ...
Nerve compression syndrome, or compression neuropathy, or nerve entrapment syndrome, is a medical condition caused by chronic, direct pressure on a peripheral nerve. [1] It is known colloquially as a trapped nerve, though this may also refer to nerve root compression (by a herniated disc, for example).
Explanatory model of chronic pain. Chronic pain is defined as reoccurring or persistent pain lasting more than 3 months. [1] The International Association for the Study of Pain (IASP) defines pain as "An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage". [2]
For neuropathic pain, clinicians look for an underlying lesion to the nervous system or an inciting cause consistent with the development of neuropathic pain. The obvious presence of an underlying feature or cause is not always detectable, and response to treatment may be used as a surrogate particularly in cases where diagnosis of the ...
Complex regional pain syndrome (CRPS Type 1 and Type 2), sometimes referred to by the hyponyms Reflex Sympathetic Dystrophy (RSD) or Reflex Neurovascular Dystrophy (RND), is a rare and severe form of neuroinflammatory and dysautonomic disorder causing chronic pain, neurovascular, and neuropathic symptoms.
Immunoglobulin and steroids are the first line choices for treatment. [citation needed] In severe cases of CIDP, when second-line immunomodulatory drugs are not efficient, autologous hematopoietic stem cell transplantation (HSCT) is sometimes performed. The treatment may induce long-term remission even in severe treatment-refractory cases of CIDP.
Gabapentin is recommended as a first-line treatment for chronic neuropathic pain by various medical authorities. [ 10 ] [ 11 ] [ 31 ] [ 32 ] This is a general recommendation applicable to all neuropathic pain syndromes except for trigeminal neuralgia , where it may be used as a second- or third-line agent.
Nefopam is contraindicated in people with convulsive disorders, those that have received treatment with irreversible monoamine oxidase inhibitors such as phenelzine, tranylcypromine or isocarboxazid within the past 30 days and those with myocardial infarction pain, mostly due to a lack of safety data in these conditions.